Navigation Links
Amgen introduces comprehensive financial assistance programs for cancer patients

Amgen today announced AmgenTM Oncology Assistance (AOA), a comprehensive, multi-faceted financial assistance program that will include a "cap" on out-of-pocket co-payments for cancer patients receiving VectibixTM (panitumumab). Through AOA, patients who are uninsured, underinsured, or unable to afford their insurance co-payments will receive help obtaining financial support for Amgen's cancer medicines.

"We recognize that treating cancer is expensive and our industry needs to find new ways to ease the financial burden on cancer patients, their families and society," said Kevin Sharer, chairman and chief executive officer at Amgen. "Our goal is to create the most comprehensive oncology access program in the industry, and we are starting with Amgen Oncology Assistance. To ensure patients have access to Vectibix, we have priced it at approximately 20 percent less than the other antibody on the market and created the Vectibix Cap, which is the first of its kind for colorectal cancer patients."

The AOA program will be available for U.S. cancer patients and will launch in October. AOA will expand and consolidate the company's existing financial assistance programs into a simplified package with a single gateway:

  • The new Vectibix Cap will limit total patient co-payments for Vectibix in the United States, regardless of income or insurance status. Once a patient reaches the cap (five percent of their adjusted gross income), he or she will become eligible for the SAFETY NET® Foundation.
  • The SAFETY NET Foundation is a well-established patient assistance program that provides Amgen oncology medicines at no cost to qualifying uninsured patients. Available to patients with household adjusted gross incomes of up to $75,000 per year, The SAFETY NET Foundation is one of the most generous oncology product donation programs in the industry.
  • Amgen also donates millions of dollars to independent third-p arty administered patient assistance programs to help reduce the financial burden for uninsured or low-income patients.

These programs build on Amgen's Reimbursement Connection®, which has been addressing the provider community's reimbursement questions regarding Amgen therapies for more than 15 years. For more information about Amgen Oncology Assistance, please visit


Source:Porter Novelli

Related biology news :

1. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
2. Agilent Technologies introduces high-capacity human protein removal system for proteomics research
3. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
4. Lipids get new comprehensive classification system
5. NIH launches comprehensive effort to explore cancer genomics
6. RNA map provides first comprehensive understanding of alternative splicing
7. LIAI completes worlds most comprehensive analysis on influenza virus data
8. Costly breeding programs for endangered species pay off
9. Investment level in HIV prevention programs related to HIV incidence in the United States
10. Viral DNA sequence a possible trigger for breast cancer
11. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
Post Your Comments:

(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology: